

# Valeo Pharma Obtains Listings for Redesca in 700 Hospitals and Healthcare Facilities Across Canada

written by Raj Shah | October 13, 2021  
October 13, 2021 ([Source](#)) –

- **2 Group Purchasing Organizations (GPO) listing agreements cover, Redesca™ and Redesca HP™, as well as 3 other Valeo hospital products**
- **The 2 multi-year product listings commenced on October 1, 2021**
- **The GPOs together represent more than 700 hospitals and healthcare facilities across 5 provinces including Ontario**

[Valeo Pharma Inc.](#) (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (“**Valeo**” or the “**Company**”), a Canadian pharmaceutical company, announced today that it has been awarded two multi-year listing agreements by two of Canada’s largest Group Purchasing Organizations (“GPO”) for Redesca as well as three additional hospital specialty products.

Under the terms of the contracts, the GPOs have listed Redesca™ and Redesca HP™, Valeo’s leading low molecular weight heparin (“LMWH”) biosimilar, as well as three other hospital products (Amikacin, Ethacrynate Sodium and Benztropine), for a 3-year period starting on October 1, 2021.

“These listing agreements significantly expand the number of Canadian hospitals that can now access Redesca. Increased hospital accessibility, coupled with extensive public and

private reimbursement coverage, provides a solid foundation to support the continued growth of Redesca. The Canadian hospital market is highly sought-after and competitive, our commercial team continues to delivery results in this environment “, said Steve Saviuk, Chief Executive Officer.

Commenting on the GPO contract signature, Frederic Fasano, President and Chief Operating Officer said, “Our new corporate structure and commercial platform allow us to successfully pursue and develop strong partnerships with leading GPO across the country and better service their evolving needs. The support provided by our dedicated team of key account managers and medical affairs professionals combined with the strong supply chain in place make Redesca’s value proposition very attractive for hospitals”.

### **About Valeo Pharma**

Valeo Pharma is a Canadian pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respiratory Diseases, Neurodegenerative Diseases, Oncology and Hospital Specialty Products. Headquartered in Kirkland, Quebec Valeo Pharma has all the required capabilities and the full infrastructure to register and properly manage its growing product portfolio through all stages of commercialization. For more information, please visit [www.valeopharma.com](http://www.valeopharma.com) and follow us on [LinkedIn](#) and [Twitter](#).

### **Forward Looking Statements**

This press release contains forward-looking statements about Valeo’s objectives, strategies and businesses that involve risks and uncertainties. These statements are “forward-looking” because they are based on our current expectations about the markets we operate in and on various estimates and assumptions.

Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

SOURCE Valeo Pharma Inc. 

For further information: Steve Saviuk, CEO, 514-693-8830 , saviuk@valeopharma.com; or Frederic Dumais, Director, Communications and Investor Relations, 514-782-8803, dumais@valeopharma.com